IMV Inc. News Releases https://ir.imv-inc.com/ IMV Inc. News Releases en IMV Inc. to Present at Two Upcoming Investor Conferences https://ir.imv-inc.com/news-releases/news-release-details/imv-inc-present-two-upcoming-investor-conferences-0 DARTMOUTH, Nova Scotia --(BUSINESS WIRE)--Jun. 13, 2019-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in June: Raymond James Life Sciences and MedTech Thu, 13 Jun 2019 17:08:00 -0400 IMV Inc. News Releases 9081 New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in Patients with DLBCL https://ir.imv-inc.com/news-releases/news-release-details/new-phase-2-clinical-trial-results-continue-demonstrate Complete radiologic responses linked to T cell activity observed in two of first six evaluable patients IMV to host investor conference call and webcast on June 12, 2019 at 8:00 am ET DARTMOUTH, Nova Scotia --(BUSINESS WIRE)--Jun. 12, 2019-- IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage Wed, 12 Jun 2019 07:05:00 -0400 IMV Inc. News Releases 9071 IMV Inc. to Provide Update on Phase 2 Clinical Results with Merck Keytruda in DLBCL by Means of Conference Call and Webcast on June 12, 2019 https://ir.imv-inc.com/news-releases/news-release-details/imv-inc-provide-update-phase-2-clinical-results-merck-keytruda DARTMOUTH, Nova Scotia --(BUSINESS WIRE)--Jun. 4, 2019-- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Wednesday, June 12, 2019 , at 8:00 a.m. ET . Tue, 04 Jun 2019 07:05:00 -0400 IMV Inc. News Releases 9041 IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival https://ir.imv-inc.com/news-releases/news-release-details/imv-inc-presents-new-positive-data-phase-2-monotherapy-arm-its Tumor regressions demonstrate potential for DPX-Survivac immunotherapy in hard-to-treat solid tumors Data correlations of survivin specific T cell levels and durable clinical benefit continue to link novel mechanism of action of DPX-Survivac with anti-cancer activity DARTMOUTH, Nova Scotia Sat, 01 Jun 2019 14:15:00 -0400 IMV Inc. News Releases 9026 IMV to Present New Data at 2019 ASCO Annual Meeting From Its Phase 2 Clinical Trial Evaluating DPX-Survivac in Ovarian Cancer https://ir.imv-inc.com/news-releases/news-release-details/imv-present-new-data-2019-asco-annual-meeting-its-phase-2 Company to host conference call following ASCO presentation on June 2 to discuss updated clinical data DARTMOUTH, Nova Scotia --(BUSINESS WIRE)--May 16, 2019-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the American Society of Clinical Thu, 16 May 2019 07:05:00 -0400 IMV Inc. News Releases 8981 IMV Inc. to Present at Upcoming Investor Conferences https://ir.imv-inc.com/news-releases/news-release-details/imv-inc-present-upcoming-investor-conferences-0 DARTMOUTH, Nova Scotia --(BUSINESS WIRE)--May 14, 2019-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in May: RBC Capital Markets Global Healthcare Tue, 14 May 2019 17:05:00 -0400 IMV Inc. News Releases 8966 IMV Announces Annual and Special Meeting of Shareholders Voting Results https://ir.imv-inc.com/news-releases/news-release-details/imv-announces-annual-and-special-meeting-shareholders-voting DARTMOUTH, Nova Scotia --(BUSINESS WIRE)--May 10, 2019-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company (or the ”Corporation”), today announced the voting results from its Annual and Special Meeting of Shareholders held on  Thursday May 9, 2019 . Fri, 10 May 2019 10:18:00 -0400 IMV Inc. News Releases 8936 IMV Inc. Announces Q1 2019 Financial Results and Clinical Program Advances https://ir.imv-inc.com/news-releases/news-release-details/imv-inc-announces-q1-2019-financial-results-and-clinical-program DARTMOUTH, Nova Scotia --(BUSINESS WIRE)--May 9, 2019-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2019 . “The DPX-Survivac program continues to be a major value-driver for IMV, Thu, 09 May 2019 17:05:00 -0400 IMV Inc. News Releases 8926 IMV Joins World Ovarian Cancer Coalition and Ovarian Cancer Canada in Supporting Ovarian Cancer Day 2019 https://ir.imv-inc.com/news-releases/news-release-details/imv-joins-world-ovarian-cancer-coalition-and-ovarian-cancer DARTMOUTH, Nova Scotia --(BUSINESS WIRE)--May 8, 2019-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today joins with World Ovarian Cancer Coalition and Ovarian Cancer Canada in recognizing World Ovarian Cancer Day (WOCD). Wed, 08 May 2019 07:05:00 -0400 IMV Inc. News Releases 8901 IMV to Provide Updated Data From Phase 2 Study Evaluating DPX-Survivac in Combination with Merck’s Keytruda® in DLBCL https://ir.imv-inc.com/news-releases/news-release-details/imv-provide-updated-data-phase-2-study-evaluating-dpx-survivac Abstract on the study accepted at the 2019 ICML Meeting DARTMOUTH, Nova Scotia --(BUSINESS WIRE)--May 3, 2019-- IMV Inc. (Nasdaq: IMV; TSX: IMV), the clinical stage immuno-oncology corporation, today announced that the 2019 International Conference on Malignant Lymphoma (ICML) will publish an Fri, 03 May 2019 07:05:00 -0400 IMV Inc. News Releases 8886